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Abstract
Background: The dendritic cell-specific intercellular adhesion molecule 3 grabbing non-integrin (DC-SIGN) is an
important pathogen recognition receptor of the innate immune system. DC-SIGN promoter variants play important
role in the susceptibility to various infectious diseases. Nasopharyngeal carcinoma (NPC) is a malignancy that is
common in southern China and whether DC-SIGN promoter variants have effects on susceptibility to NPC is still
unknown. The aim of this study is to ascertain the potential involvement of DC-SIGN promoter single nucleotide
polymorphisms (SNPs) in NPC susceptibility.
Methods: We conducted a case control study based on Cantonese population including 444 NPC patients and
464 controls matched on age and sex. The 1041 bp of DC-SIGN promoter region was directly sequenced for all
samples. Sequence alignment and SNP search were inspected using DNAStar analysis programs and haplotype
frequencies were estimated in Haploview V 4.0. The associations between the SNPs and the risk of NPC were
analyzed using chi-square test and non-conditional logistic regression analysis with SPSS 13.0 software.
Results: A total of six variants were observed in the DC-SIGN promoter region and DC-SIGN -139 GG and -939 AA
were significantly associated with NPC risk with adjusted Odds Ratios (ORs) of 2.10 (95% confidence interval [CI] =
1.23-3.59; P = 0.006) and 2.52 (1.29-4.93; P = 0.007) respectively and subjects carrying the risk allele DC-SIGN -871 G
had 1.47-fold (95% CI = 1.14-1.90) increased risks of developing NPC (P = 0.003). Haplotype analysis revealed that
h1 ‘AAAG’ was significantly associated with protection against NPC (OR = 0.69; P = 0.0002) and the association was
still significant when using 1000 permutation test runs (P = 0.001).
Conclusions: Our study indicated that DC-SIGN promoter variants appear to be involved in the susceptibility to
NPC and the detailed mechanism of this effect need further studies.
Background
Nasopharyngeal carcinoma (NPC) is rare in most popu-
lations around the world but common in China and
Southeast Asia, where the incidence can reach 20 to 50
per 100,000 individuals [1-5]. Epstein-Barr virus (EBV)
is considered a major risk factor for NPC, and there is a
dose-response relationship between EBV antibodies and
NPC risk [6,7]. EBV is present in over 90% of the world
population [8], most often as a form of in vivo latency
in healthy carriers with low copies of episomal virus
maintained in resting memory B cells [9-11].
DC-SIGN (Dendritic cell-specific intercellular adhesion
molecule 3 grabbing non-integrin), encoded by CD209
on chromosome 19p13.3, is a C-type lectin that is
expressed on subsets of dendritic cells (DCs) and alveo-
lar macrophages [12-15], and functions both as a cell
adhesion receptor and as a pathogen recognition recep-
tor [16]. Acting as a pathogen uptake receptor, DC-
SIGN could mediate interactions with a plethora of
pathogens [17] including bacteria such as Helicobacter
pylori [18]; viruses such as HIV-1 [19], Ebola [20,21],
Cytomegalovirus [22], Hepatitis-C virus [23,24], Dengue
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virus [20,21,25], and SARS-coV [26], and parasites such
as Leishmania pifanoi [27]. Several studies have recently
reported on the role of DC-SIGN promoter variants in
the susceptibility to or pathogenesis of various infectious
diseases, such as dengue fever [25,28], tuberculosis
[13,14,29,30], Acquired Immune Deficiency Syndrome
(AIDS) [19,31-33], celiac disease [34]. Sakuntabhai et al.
[25] reported that the G allele of the variant DC-SIGN
-336 was associated with strong protection against den-
gue fever [35]. In addition, several previous reports sug-
gested that variants in the DC-SIGN promoter conferred
protection against tuberculosis [29,30]. However,
whether DC-SIGN promoter variants have effects on
susceptibility to NPC is still unknown and so far no
study has reported on the variants in the DC-SIGN pro-
moter in Cantonese population.
Therefore, we explored the relationship between DC-
SIGN promoter polymorphisms and susceptibility to
NPC by determining DC-SIGN promoter sequence var-
iation in a case-control study in Cantonese.
Methods
Study subjects
All subjects were unrelated Cantonese population in
Guangdong Province, China. Cases were recruited con-
secutively from December 2005 to October 2006 with
pathologically confirmed diagnosis of NPC at the Sun
Yat-Sen University Cancer Center (SYSUCC), Guangz-
hou, China. Total 500 NPC patients were collected and
444 were Cantonese origin living in Southern China.
Population controls were cancer-free individuals, ran-
domly selected from individuals who attend annual
community-based physical examinations during the
same time period. The selection criteria for control sub-
jects included no individual history of cancer, all of
them were Cantonese, and matched to NPC cases by
age (± 5 years), sex and the time period for blood sam-
ple collection. Total 464 controls were involved. All
study subjects had signed informed consent agreements
before epidemiological data and blood samples were col-
lected by trained SYSUCC staff interviewers.
For both cases and controls, venous blood specimens
totalling 5-10 ml were collected from subjects and geno-
mic DNA was then extracted from the lymphocytes
using the QIAamp DNA Blood Midi Kit (Qiagen, Ger-
man) following the manufacturer’s protocol. These pro-
cedures were reviewed and approved by the Human
Ethics Approval Committee of SYSUCC.
Genotyping of DC-SIGN promoter variants
A region approximately 1,041 bp upstream of the ATG
start codon that includes the promoter region was
amplified using the following primers: 5- ‘GCAGTCTT-
GGTTCCTTGGAG -3’ for forward primer 1 and 5-
‘ACTTGCAGTGCCTCCTCAGT -3’ for reverse primer
1; 5’-TGCTGCTGTCCTCATTTTTG-3’ for forward pri-
mer 2 and 5’-AGCATACAGAAACCCCGTTG-3’ for
reverse primer 2. Primer 1 delimits the promoter region
between nt -602 and 28 [GenBank: NC_000019.9)] and
amplifies a 630 bp fragment. Primer 2 delimits the pro-
moter region between nt -404 and nt -1041 and ampli-
fies a 638 bp fragment. Polymerase chain reaction (PCR)
amplification was performed in a volume of 20 μL as
follows: 15.85 μL ddH2O, 2.0 μL 10 × reaction buffer
(with Mg2+), 0.5 μL 4 × dNTP (10 mmol L-1), 0.2 μL of
each primer (20 μM), 1.25 U Taq DNA polymerase, and
1 μL genomic DNA (20 ng). Touchdown PCR was per-
formed in the model 9700 GeneAmp PCR system
(Applied Biosystems, Foster City, CA) with the following
conditions: one initial denaturation of 95°C for 5 min-
utes, and then 5 cycles of 94°C for 30 seconds, 61°C for
30 seconds (-0.5°C every cycle), and 72°C for 45 sec-
onds; then 32 cycles of 94°C for 30 seconds, 60°C for 30
seconds, and 72°C for 45 seconds, followed by one elon-
gation step at 72°C for 10 minutes. The amplified pro-
ducts were analysed by 1.5% agarose gel electrophoresis
followed by ethidium bromide staining. PCR amplifica-
tion was performed using the same conditions for pri-
mer 1 and primer 2 as described above.
PCR products were recovered, and further purified.
Sequencing reactions were performed using PCR pri-
mers and all nucleotide sequences were obtained using
the 3730 automated sequencer (Applied Biosystems).
Sequence alignment and SNP search were inspected
using DNAStar analysis programs (DNAStar, Madison,
WI, USA) using the nucleic acid sequences from Gene-
bank at National Center for Biotechnology Information
(NCBI) as the prototype sequence [GenBank:
NC_000019.9].
Statistical analysis
To test the different promoter polymorphisms of DC-
SIGN gene for a possible distortion in genotypic and
allelic frequencies between cases and controls, a chi-
square test or Fisher’s exact test was used to compare
the genotypic and allelic distribution between cases and
controls. In addition, to control confounding factors,
unconditional logistic regression analysis was conducted
to compare the genotype frequencies between cases and
controls by adjusting for age, sex, the level of educa-
tional. The analyses were performed in SPSS software
for Windows, version 13.0 (SPSS). For power calcula-
tion, the QUANTO program (Version 1.2) was used.
Haplotype frequencies were estimated using the accel-
erated expectation maximisation algorithm implemented
in Haploview V 4.0 [36]. Haplotype frequencies occur-
ring at <5% were excluded from the analysis. Associa-
tion testing for the haplotypes was performed using the
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chi-square test. ORs were calculated with 95% CI. Sig-
nificant associations were defined as P < 0.05 and all
statistical tests were two-tailed.
Results
This study included a total of 444 NPC patients and 464
control subjects. The characteristics of study subjects
are summarised in Table 1. The mean age (± standard
deviation) of the patients was 41.7 ± 9.6 y and 61.0% of
the cases were male. For controls, the age was 41.3 ±
10.6 y and 60.1% of subjects were male. There was no
statistically significant difference between cases and con-
trols with respect to the frequency distributions of age
and the sex distribution was unbiased (all P-values >
0.05). There was significant association between the
level of education and NPC susceptibility. In current
study, 21.7% of the case patients versus 8.0% of control
subjects were illiterate or had an education of primary
school (P < 0.001).
Direct sequencing of the promoter region of DC-SIGN
revealed the occurrence of six variants: -939 G/A, -871
A/G, -336 A/G, -190 A/G, -139 A/G and -116 G/T.
Table 2 presents detailed information on these six var-
iants. The minor allele frequencies (MAFs) of all SNPs
evaluated in the DC-SIGN promoter were >0.05 except
for -190 A/G (MAF = 0.003) and -116 G/T (MAF =
0.006), and all loci fit Hardy-Weinberg equilibrium
expectations (P-values > 0.05).
Table 3 presents the genotypic and allelic frequencies
of these six variants among Cantonese population. For
DC-SIGN -139 A/G, subjects carrying mutant genotype
-139 AG, which means a SNP -139 A/G in heterozygous
alleles and -139 GG, which means a SNP -139 A/G in
both G alleles, had 1.42-fold (95% CI = 1.07-1.86) and
1.99-fold (95% CI = 1.20-3.30) increased risks of devel-
oping NPC, respectively, when compared with those car-
rying wild genotype -139 AA. After adjusting for age,
sex and the level of education, genotype -139 AG and
-139 GG had 1.41-fold (95% CI = 1.05-1.88) and 2.10-
fold (95% CI = 1.23-3.59) increased risks of developing
NPC, respectively, when compared with those carrying
wild genotype -139 AA (P trend = 0.005). Furthermore,
subjects carrying the risk allele -139 G had 1.42-fold
(95% CI = 1.15-1.74) increased risks of developing NPC
when compared with those carrying allele -139 A (P =
0.001). In addition, subjects possessing mutant genotype
-871 AG and GG had higher risks of developing NPC
(OR = 1.43; 95% CI = 1.06-1.93 and OR = 2.34; 95% CI
= 0.99-5.54, respectively) when compared with those
carrying wild genotype -871 AA and those carrying the
risk allele -871 G had 1.47-fold (95% CI = 1.14-1.90)
increased risks of developing NPC when compared with
those carrying allele -871 A (P = 0.003). After adjusting
for age, sex and the level of education, there was no sig-
nificant association between -871 GG genotype and
NPC susceptibility (P = 0.14), which maybe mainly due
to the small sample size. However, the association
between -871 AG genotype and NPC susceptibility was
still significant (P = 0.03). For DC-SIGN -939 G/A, sub-
jects carrying mutant genotype -939 AA had a 2.56-fold
increased risk of developing NPC (OR = 2.56; 95% CI =
1.36-4.83; P = 0.003) compared to those carrying wild-
type genotype -939 GG and the association is still signif-
icant after adjusting for age, sex and the level of educa-
tion (OR = 2.52; 95% CI = 1.29-4.93; P = 0.007).
Furthermore, the association between the risk allele
-939 A and NPC susceptibility was statistically signifi-
cant (OR = 1.43; 95% CI = 1.15-1.79; P = 0.002). How-
ever, for the other three SNPs, there were no significant
differences between cases and controls. For power calcu-
lation, the powers for all of the three significant SNPs,
DC-SIGN-139, -871 and -939, were 0.92, 0.87 and 0.90,
respectively.
Moreover, we performed the analyses at the haplotype
level and found that there was significant linkage dise-
quilibrium among DC-SIGN -139 A/G, -336 A/G, -871
A/G and -939 G/A, and a block was constructed by
these four SNPs (Figure 1). Table 4 shows the results of
haplotype analysis and reveals that h1 ‘AAAG’, repre-
senting wild-type for all four common SNPs (-139 A,
-336 A, -871 A and -939 G) and accounting for 68.4%
of all haplotypes, was associated with protection against
NPC (OR = 0.69; 95% CI = 0.57- 0.84; P = 2.0 × 10-4).
Further, using 1000 permutation test runs, we also
detected a significant association (P = 0.001) between
this haplotype and NPC phenotype. In addition, h2
‘GAGA’, which accounts for 14.1% of all haplotypes, was
associated with NPC risk (OR = 1.34; 95% CI = 1.03-
Table 1 Demographic characteristics and socio-economic







Male 271 (61.0) 279 (60.1) 0.78
Female 173 (39.0) 185 (39.9)
Age(%), mean ± SD (y) 41.7 ± 9.6 41.3 ± 10.6
≤30 49 (11.0) 61(13.1) 0.71
31-40 163 (36.7) 158 (34.1)
41-50 162 (36.5) 163 (35.2)
51-60 51 (11.5) 60 (12.9)
61~ 19 (4.3) 22 (4.8)
Level of education
Illiteracy or primary school 94 (21.7) 37 (8.0) <0.001
High school 268 (61.8) 255 (55.1)
University or above 72 (16.6) 171 (36.9)
*P- values were calculated using the chi-square test.
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Table 2 The minor allele frequencies and Hardy-Weinberg equilibrium tests of 6 variants in DC-SIGN gene
Polymorphism NCBI rs number Position† Genotype‡ Gene region MAF § PH-W¶ % Geno -typed
Code Name
1 DC-SIGN -116 – 7718513 G/T Promoter 0.006 1.00 100.0
2 DC-SIGN -139 rs2287886 7718536 A/G Promoter 0.275 0.64 100.0
3 DC-SIGN -190 – 7718587 A/G Promoter 0.003 1.00 100.0
4 DC-SIGN -336 rs4804803 7718733 A/G Promoter 0.085 0.96 100.0
5 DC-SIGN -871 rs735239 7719268 A/G 5’flanking 0.154 0.58 100.0
6 DC-SIGN -939 rs735240 7719336 G/A 5’flanking 0.222 0.71 100.0
†The chromosome position listed here is taken from the NCBI database dbSNP build 130.
‡ First allele is major allele, the second is minor allele.
§ MAF denotes Minor Allele Frequency.
¶PH-W represents the P value of Hardy-Weinberg equilibrium tests.
Table 3 Association between DC-SIGN promoter variants and NPC
SNP Genotype Case Control UnadjustedOR (95% CI)* Unadjusted P-value* Adjusted OR (95% CI) # Adjusted P-value #
DC-SIGN -116 GG 440 457 ref ref
GT 4 7 0.59(0.17-2.04) 0.40 0.57 (0.16-2.01) 0.38
TT 0 0 – – – –
Allele G 884 921 ref
T 4 7 0.60(0.17-2.04) 0.40 – –
DC-SIGN -139 AA 212 268 ref ref
AG 188 168 1.42 (1.07-1.86) 0.01 1.41 (1.05-1.88) 0.02
GG 44 28 1.99 (1.20-3.30) 0.007 2.10 (1.23-3.59) 0.006
P trend = 0.005
Allele A 612 704 ref
G 276 224 1.42 (1.15-1.74) 0.001 – –
DC-SIGN -190 AA 441 462 ref ref
AG 3 2 1.57 (0.26-9.45) 0.68 1.57 (0.24-10.36) 0.64
GG 0 0 – – – –
Allele A 885 926 ref
G 3 2 1.57 (0.26-9.42) 0.68 – –
DC-SIGN -336 AA 365 396 ref ref
AG 77 63 1.33 (0.92-1.91) 0.13 1.43 (0.98-2.09) 0.07
GG 2 5 0.43 (0.08-2.25) 0.45 0.57 (0.11-3.07) 0.51
P trend = 0.14
Allele A 807 855 ref
G 81 73 1.18 (0.85-1.64) 0.34 – –
DC-SIGN -871 AA 301 352 ref ref
AG 127 104 1.43(1.06-1.93) 0.02 1.44 (1.05-1.98) 0.03
GG 16 8 2.34 (0.99-5.54) 0.05 1.97 (0.80-4.88) 0.14
P trend = 0.04
Allele A 729 808 ref
G 159 120 1.47 (1.14-1.90) 0.003 – –
DC-SIGN -939 GG 251 301 ref ref
AG 161 148 1.31 (0.99-1.72) 0.06 1.28 (0.95-1.71) 0.11
AA 32 15 2.56 (1.36-4.83) 0.003 2.52 (1.29-4.93) 0.007
P trend = 0.01
Allele G 663 750 ref
A 225 178 1.43 (1.15-1.79) 0.002 – –
* Odds ratios and P- values were calculated using the chi-square test.
# Odds ratios and P-Values were calculated by adjusting for age, sex, educational level.
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1.75; P = 0.03). However, when using using 1000 per-
mutation test runs, there was no significant association
between h2 ‘GAGA’ and NPC phenotype (P = 0.23).
Discussion
This report on the distribution of genetic polymorph-
isms in the DC-SIGN promoter in the Cantonese popu-
lation revealed that DC-SIGN -139 GG and -939 AA
were significantly associated with increased risk of NPC
and the risk allele DC-SIGN -871 G was significantly
associated with NPC susceptibility (Table 3). Haplotype
analysis revealed that h1 ‘AAAG’, which contains all
four wild-type SNPs (-139 A, -336 A, -871 A and -939
G), was associated with a significantly decreased risk of
NPC and h2 ‘GAGA’ was significantly associated with
the NPC phenotype (Table 4). Moreover, we found two
new variants in Cantonese population, -116 G/T and
-190 A/G, although the MAFs for both were low (0.6%
and 0.3%, respectively).
In current study, the MAFs of four common SNPs
(-139 A/G, -336 A/G, -871 A/G and -939 G/A) in the
promoter region of DC-SIGN in Cantonese population
were similar to that in 45 unrelated Han Chinese in
Beijing, China (HCB) http://www.ncbi.nlm.nih.gov/pro-
jects/SNP/snp. In addition, Kashima et al. [37] found
that the allelic frequency of DC-SIGN -332 A was
10.7% by sequencing 28 Asians; however, this SNP was
neither detected by Barreiro et al. in Asians [30] nor
by Koizumi et al. in Japanese individuals [31]. Equally,
this SNP is not detected in individuals of Cantonese in
current study, which indicates that DC-SIGN -332 A is
not widespread in most Asians. Two other SNPs in the
promoter region, DC-SIGN -745 G/T and -201 G/T,
were not present in current cohort, though they were
observed exclusively in the Zimbabwean population
[38]. The allelic distribution of DC-SIGN genes differs
widely in populations from different ethnic groups,
presumably the result of selective pressure exerted by
prevalent pathogens in these geographically distinct
regions. NPC is rare in most populations around the
world but common in China and Southeast Asia and
this could be reflected in SNP frequencies. DC-SIGN, a
protein expressed on the surface of DCs, has recently
received considerable attention in research on AIDS
[33], dengue [25,35], tuberculosis [29,30] and Ulcera-
tive Colitis [39]. Previous studies have indicated that
DC-SIGN -336 G is associated with protection against
dengue disease in Thailand population [25] and tuber-
culosis disease in sub-Saharan Africa individuals [29].
It may mainly due to the location of the DC-SIGN
-336 SNP 214 bp upstream of the major transcription
site, affecting a Sp1-like binding site and further mod-
ulating DC-SIGN transcriptional activity [25]. However,
Figure 1 LD block structure around DC-SIGN promoter region.
Haplotype block structure, as depicted by Haploview, is shown. The
three-color scheme (white to red) represents the increasing strength
of LD. Values for D’ is shown, those boxes with D’ = 1 are shaded in
bright red and blank. Cells with D’ < 1 are shades of pink or red
with 100 × D’ indicated.
Table 4 Association between DC-SIGN Haplotypes and NPC risk
Hap† Block HaploFreq ‡ Case Ratios Control Ratios Chisq OR (95% CI) P-value* EMP ¶
h1 AAAG 0.684 0.643 0.723 13.6 0.69 (0.57-0.84) 2.0 × 10-4 0.001
h2 GAGA 0.141 0.159 0.124 4.70 1.34 (1.03-1.75) 0.03 0.23
h3 GGAG 0.084 0.091 0.078 1.06 1.19 (0.85-1.66) 0.30 0.92
† The code of each haplotype.
‡The frequency of each haplotype.
*P- values were calculated using the chi-square test.
¶EMP = 1,000 permutation test P value.
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Barreiro and colleagues [30] found that -336 A and
-871 G variants conferred protection against tuberculo-
sis in Eurasian populations. Meriem Ben-Ali et al. [40]
found no association between DC-SIGN promoter var-
iation and susceptibility to tuberculosis in Tunisian
patients. These contrasting results may be due to sig-
nificant differences in the distribution of DC-SIGN
alleles in different ethnic populations [38]. Different
population genetic backgrounds as well as differences
in linkage disequilibrium (LD) patterns can be at the
basis of the conflicting results. In current study, there
was no observable association between DC-SIGN -336
SNP and NPC susceptibility in the Cantonese
population.
The mechanism of involvement of mutant DC-SIGN
-139 and 939 in the pathogenesis of NPC remains
unknown. Previous studies have already demonstrated a
higher frequency of allele DC-SIGN -139 A in indivi-
duals not infected with HIV compared with infected
patients [32]. In another study, allele -139 G was found
to be associated with the rapid progression of AIDS in a
population of Japanese haemophiliacs [31]. In current
study, we found that the frequencies of DC-SIGN -139
GG and -939 AA were significantly higher in NPC
patients compared with healthy controls. One potential
mechanism for this effect may involve differential indu-
cible expression of DC-SIGN on blood DCs as a result
of these two polymorphisms, but this remains to be
demonstrated. DC-SIGN -139 is located close to one of
the binding sites of the transcription factor AP-1 in the
promoter region of DC-SIGN, and we could speculate
that the substitution of one nucleotide close to this site
may change the level of expression of DC-SIGN and
further contribute to the progression of NPC. As for
DC-SIGN -939, it is yet to be determined whether this
variant will affect the expression of DC-SIGN.
EBV is an important etiological agent of NPC and
establishes persistent infections by employing multiple
strategies to evade host immune responses. Consistent
with the critical function of DCs in anti-viral immunity,
myriad viruses are known to infect different subsets of
DCs and to affect their differentiation, survival, and
migration and/or T cell stimulatory capacity [41-44].
However, no studies have been performed so far to
determine whether DC-SIGN is the EBV receptor. EBV
has been observed to infect DC-SIGN positive cells such
as immature DCs [45], monocytes [46-48] and some
macrophages [49-51]. Furthermore, Li et al. [45]showed
that EBV infection inhibited DC development from
monocyte precursors, and further showed that immature
DCs that become resistant to EBV-induced apoptosis
still support virus entry [50]. Guerreiro-Cacais AO et al
reported that EBV-infected macrophages could facilitate
dissemination of EBV within the oral mucosal
epithelium [50]. Recently, DC-SIGN could serve as puta-
tive receptor for secretory IgA (SIgA) on immature DCs
by binding to high mannose glycoprotein on SIgA pro-
tein has been reported [52]. Sixbey JW et al have
demonstrated that EBV-SIgA complex promoted EBV
infection of epithelial cells through secretory compo-
nent-mediated IgA transport [53]. We hypothesize that
DC-SIGN expressed on immature DCs may recognize
EBV-SIgA complex though binding to SIgA and thus
promote EBV infection of immature DCs. This link DC-
SIGN to EBV infection of immature DCs was need
further confirmed and the study is on the way in our
Lab.
We would like to point out that the sample size of the
current study was not large enough and these results
need to be validated in larger samples. Despite limita-
tions, the current study represents the first comprehen-
sive genetic association study examining the relationship
between DC-SIGN promoter genetic variants and NPC
risk in a case-control study and supplying genetic data
of DC-SIGN promoter polymorphism in Cantonese
population.
Conclusions
Our study shows that the mutant genotypes -139 GG
and -939 AA detected in the promoter region of the
DC-SIGN gene were involved in NPC susceptibility, and
further studies are necessary to demonstrate the role of
DC-SIGN promoter polymorphisms in the function of
DC-SIGN as well as their effect on EBV infection.
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